Short and Long Term Effects of a DPP-4 Inhibitor Versus Bedtime NPH Insulin as ADD-ON Therapy in Patients with Type 2 Diabetes

Imagem de Miniatura
Arquivos
art_SILVA_Short_and_Long_Term_Effects_of_a_DPP4_2016.PDF (2.06 MB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2016
Editora
BENTHAM SCIENCE PUBL LTD
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
NOGUEIRA, Katia Camarano
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
CURRENT PHARMACEUTICAL DESIGN, v.22, n.44, p.6716-6721, 2016
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: We conducted a comparison between the dipeptidyl-peptidase-4(DPP-4) inhibitor sitagliptin versus NPH insulin as an add-on therapies in patients with type 2 diabetes mellitus (T2D) failing oral medications. The objective was to ascertain the better indication in long-duration diabetes. Methods: thirty-five T2D patients inadequately controlled with metformin plus glyburide were randomized to receive sitagliptin (n=18) or bedtime NPH insulin (n=17) for 12 months. HbA1c levels and a metabolic and hormonal profile at fasting and post-meal (every 30 minutes for 4 hours) were evaluated before and after 6 months (short-term) and 12 months (long-term) after adding sitagliptin or bedtime NPH insulin to their drug regime. Results: Sitagliptin and NPH insulin decreased HbA1c levels equally after 6 months (p<0.001) with no further improvement after 12 months: sitagliptin (8.1 +/- 0.7% vs. 7.3 +/- 0.8% vs. 7.4 +/- 1.9%) and insulin (8.1 +/- 0.6% vs. 7.3 +/- 0.7% vs. 7.2 +/- 1.0%). Fasting glucose, fasting and postprandial triglyceride and C-peptide levels were also reduced by NPH insulin whereas postprandial insulin was decreased by sitagliptin. Body weight and postchallenge free fatty acid levels increased with insulin treatment. The transitory suppression (at 6 months) of postprandial proinsulin levels with both therapies, and of glucagon with sitagliptin, was followed by values similar or worse to those at pre-treatment. Conclusion: The use of either NPH insulin or a DPP-4 inhibitor as add-on treatments improves glucose control in patients with T2D failing on metformin plus glyburide therapy. The results were not attributed to a permanent improvement in alpha or beta cell function in patients with long-duration diabetes.
Palavras-chave
Type 2 diabetes mellitus, dipeptidyl-peptidase-4 inhibitor, bedtime NPH insulin, glucagon-like peptide 1, glucagon, C peptide, Proinsulin
URI
https://observatorio.fm.usp.br/handle/OPI/19039
Referências
  1. American Diabetes Association, 2015, DIABETES CARE S1, V38, pS8, DOI 10.2337/DC15-S005
  2. Aulinger BA, 2014, DIABETES, V63, P1079, DOI 10.2337/db13-1455
  3. Bagger JI, 2014, DIABETOLOGIA, V57, P1720, DOI 10.1007/s00125-014-3264-2
  4. Balas B, 2007, J CLIN ENDOCR METAB, V92, P1249, DOI 10.1210/jc.2006-1882
  5. Campbell JE, 2015, NAT REV ENDOCRINOL, V11, P329, DOI 10.1038/nrendo.2015.51
  6. Inoguchi T, 2000, ENDOCR J, V47, P763, DOI 10.1507/endocrj.47.763
  7. Jamison RA, 2011, AM J PHYSIOL-ENDOC M, V301, pE1174, DOI 10.1152/ajpendo.00175.2011
  8. Kramer CK, 2015, J CLIN ENDOCR METAB, V100, P3702, DOI 10.1210/jc.2015-2725
  9. Kramer CK, 2015, J CLIN ENDOCR METAB, V100, P2987, DOI 10.1210/jc.2015-1947
  10. Kramer CK, 2014, DIABETES CARE, V37, P1076, DOI 10.2337/dc13-2339
  11. Kumar KV, 2014, DIABETES METAB SYNDR, V9, P277
  12. Linn T, 2008, J CLIN ENDOCR METAB, V93, P3839, DOI 10.1210/jc.2007-2871
  13. Lucidi P, 2011, DIABETES CARE, V34, P1312, DOI 10.2337/dc10-1911
  14. Machado HA, 2012, CLINICS, V67, P711, DOI 10.6061/clinics/2012(07)03
  15. Martin JH, 2011, INTERN MED J, V41, P299, DOI 10.1111/j.1445-5994.2011.02439.x
  16. Merovci A, 2014, J CLIN INVEST, V124, P509, DOI 10.1172/JCI70704
  17. Murase Y, 2004, INTERNAL MED, V43, P779, DOI 10.2169/internalmedicine.43.779
  18. Muscelli E, 2012, J CLIN ENDOCR METAB, V97, P2818, DOI 10.1210/jc.2012-1205
  19. Neter J, 1996, IRWIN SERIES STAT, V4, P1408
  20. Nogueira KC, 2014, DIABETOL METAB SYNDR, V6, DOI 10.1186/1758-5996-6-103
  21. ORSKOV C, 1986, ENDOCRINOLOGY, V119, P1467
  22. Plosker GL, 2014, DRUGS, V74, P223, DOI 10.1007/s40265-013-0169-1
  23. Prigeon RL, 2003, AM J PHYSIOL-ENDOC M, V285, pE701, DOI 10.1152/ajpendo.00024.2003
  24. Retnakaran R, 2010, DIABETES OBES METAB, V12, P909, DOI 10.1111/j.1463-1326.2010.01254.x
  25. Salehi M, 2011, DIABETES, V60, P2308, DOI 10.2337/db11-0203
  26. Scheen AJ, 2011, POSTGRAD MED, V125, P7
  27. Singer JM, 2000, HANDB STAT, V18, P115, DOI 10.1016/S0169-7161(00)18007-1
  28. Turner RC, 1999, JAMA-J AM MED ASSOC, V281, P2005, DOI 10.1001/jama.281.21.2005
  29. Vollmer K, 2008, DIABETES, V57, P678, DOI 10.2337/db07-1124
  30. Williams-Herman D, 2012, DIABETES OBES METAB, V14, P67, DOI 10.1111/j.1463-1326.2011.01492.x

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - LIM/18
Artigos e Materiais de Revistas Científicas - ODS/03